Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nrclinonc.2016.36 http://scihub22266oqcxt.onion/10.1038/nrclinonc.2016.36 C5529102!5529102!27000958     free     free     free       Nat+Rev+Clin+Oncol 2016 ; 13 (6): 370-83 Nephropedia Template TP {{tp|p=27000958|t=2016. Driving CAR T-cells forward |pdf=|usr=}}{{27000958}} gab.com Text Driving CAR T-cells forward JO: Nat Rev Clin Oncol http://www.kidney.de/pget.php?&tw=1&pmid=27000958 #FOAvip The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B-cell malignancies have generated an increased enthusiasm for this approach. Important lessons have been derived from clinical trials of CD19-specific CAR T cells, and ongoing clinical trials are testing CAR designs directed at novel targets involved in haematological and solid malignancies. In this Review, we discuss these trials and present strategies that can increase the antitumour efficacy and safety of CAR T-cell therapy. Given the fast-moving nature of this field, we only discuss studies with direct translational application currently or soon-to-be tested in the clinical setting. Twit Text FOAVip Driving CAR T-cells forward ????Nat Rev Clin Oncol http://www.kidney.de/pget.php?&tw=1&pmid=27000958 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27000958 #FOAvip English Wikipedia <ref>{{Cite pmid|27000958}}</ref> Driving CAR T-cells forward #MMPMID27000958 Jackson HJ; Rafiq S; Brentjens RJ Nat Rev Clin Oncol 2016[Jun]; 13 (6): 370-83 PMID27000958show ga The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the treatment of patients with cancer showed modest results, but the impressive outcomes of several trials of CD19-targeted CAR T cells in the treatment of patients with B-cell malignancies have generated an increased enthusiasm for this approach. Important lessons have been derived from clinical trials of CD19-specific CAR T cells, and ongoing clinical trials are testing CAR designs directed at novel targets involved in haematological and solid malignancies. In this Review, we discuss these trials and present strategies that can increase the antitumour efficacy and safety of CAR T-cell therapy. Given the fast-moving nature of this field, we only discuss studies with direct translational application currently or soon-to-be tested in the clinical setting. äDriving CAR T-cells forward (epmc).pdf DeepDyve Pubget Overpricing